{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"206"}],"units":"Participants"}],"description":"Blood samples were collected to determine the presence of ADAs for durvalumab using validated assays. Treatment-emergent ADA-positive was defined as either treatment-induced (post-baseline ADA-positive only) or treatment-boosted ADA (baseline positive ADA titer that was boosted to ≥4 fold during the study period). Treatment-induced ADA was defined as ADA positive post-baseline and not detected at baseline. Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher level (greater than the analytical variance of the assay) following drug administration. Number of participants with treatment-emergent ADA (ADA incidence) are presented.","groups":[{"description":"Participants received durvalumab monotherapy (1500 mg for participants \\>30 kg in weight and a weight-based dosing equivalent to 20 mg/kg for participants \\<=30 kg in weight) via IV infusion once q4w, until clinical/RECIST 1.1-defined radiological progression, intolerable toxicity, or for a maximum of 24 months, whichever occurred first.","id":"OG000","title":"Durvalumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The ADA population included all participants in the safety analysis set who had non-missing baseline ADA and at least 1 non-missing post-baseline ADA result of the study drug.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug (Day 1) up to DCO date 15 January 2024 (a maximum of approximately 1936 days)","title":"Durvalumab: Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab","type":"SECONDARY","unitOfMeasure":"Participants"}